nodes	percent_of_prediction	percent_of_DWPC	metapath
Phentolamine—ADRA1B—vas deferens—prostate cancer	0.105	0.445	CbGeAlD
Phentolamine—NISCH—prostate gland—prostate cancer	0.0109	0.0466	CbGeAlD
Phentolamine—NISCH—Paclitaxel—Cabazitaxel—prostate cancer	0.0096	0.555	CbGdCrCtD
Phentolamine—ADRA1D—prostate gland—prostate cancer	0.00914	0.0389	CbGeAlD
Phentolamine—NISCH—urethra—prostate cancer	0.00733	0.0312	CbGeAlD
Phentolamine—ADRA1D—epithelium—prostate cancer	0.00671	0.0286	CbGeAlD
Phentolamine—SIGMAR1—prostate gland—prostate cancer	0.00637	0.0271	CbGeAlD
Phentolamine—ADRA1B—renal system—prostate cancer	0.00637	0.0271	CbGeAlD
Phentolamine—ADRA1D—urethra—prostate cancer	0.00612	0.026	CbGeAlD
Phentolamine—NISCH—bone marrow—prostate cancer	0.00564	0.024	CbGeAlD
Phentolamine—SIGMAR1—seminal vesicle—prostate cancer	0.00539	0.0229	CbGeAlD
Phentolamine—ADRA1A—prostate gland—prostate cancer	0.00525	0.0223	CbGeAlD
Phentolamine—ADRA2C—prostate gland—prostate cancer	0.005	0.0213	CbGeAlD
Phentolamine—NISCH—testis—prostate cancer	0.00482	0.0205	CbGeAlD
Phentolamine—SIGMAR1—urethra—prostate cancer	0.00426	0.0182	CbGeAlD
Phentolamine—ADRA2C—seminal vesicle—prostate cancer	0.00423	0.018	CbGeAlD
Phentolamine—ADRA2A—prostate gland—prostate cancer	0.00399	0.017	CbGeAlD
Phentolamine—NISCH—Paclitaxel—Docetaxel—prostate cancer	0.00399	0.23	CbGdCrCtD
Phentolamine—ADRA1A—epithelium—prostate cancer	0.00386	0.0164	CbGeAlD
Phentolamine—ADRA1A—renal system—prostate cancer	0.00358	0.0152	CbGeAlD
Phentolamine—NISCH—lymph node—prostate cancer	0.0035	0.0149	CbGeAlD
Phentolamine—ADRA2C—renal system—prostate cancer	0.00341	0.0145	CbGeAlD
Phentolamine—ADRA2A—seminal vesicle—prostate cancer	0.00338	0.0144	CbGeAlD
Phentolamine—ADRA2C—urethra—prostate cancer	0.00335	0.0143	CbGeAlD
Phentolamine—SIGMAR1—bone marrow—prostate cancer	0.00328	0.014	CbGeAlD
Phentolamine—SIGMAR1—testis—prostate cancer	0.00281	0.0119	CbGeAlD
Phentolamine—ADRA2A—urethra—prostate cancer	0.00267	0.0114	CbGeAlD
Phentolamine—NISCH—Podofilox—Etoposide—prostate cancer	0.00256	0.148	CbGdCrCtD
Phentolamine—ADRA2C—testis—prostate cancer	0.0022	0.00938	CbGeAlD
Phentolamine—SIGMAR1—lymph node—prostate cancer	0.00203	0.00866	CbGeAlD
Phentolamine—ADRA2A—testis—prostate cancer	0.00176	0.00748	CbGeAlD
Phentolamine—ADRA2C—lymph node—prostate cancer	0.0016	0.0068	CbGeAlD
Phentolamine—Dizziness—Degarelix—prostate cancer	0.0013	0.00237	CcSEcCtD
Phentolamine—Gastrointestinal pain—Bicalutamide—prostate cancer	0.0013	0.00237	CcSEcCtD
Phentolamine—Headache—Estradiol valerate/Dienogest—prostate cancer	0.0013	0.00237	CcSEcCtD
Phentolamine—ADRA2A—lymph node—prostate cancer	0.00127	0.00543	CbGeAlD
Phentolamine—Diarrhoea—Cabazitaxel—prostate cancer	0.00127	0.00231	CcSEcCtD
Phentolamine—Acute coronary syndrome—Mitoxantrone—prostate cancer	0.00126	0.0023	CcSEcCtD
Phentolamine—Abdominal pain—Bicalutamide—prostate cancer	0.00126	0.00229	CcSEcCtD
Phentolamine—Myocardial infarction—Mitoxantrone—prostate cancer	0.00126	0.00229	CcSEcCtD
Phentolamine—Vomiting—Degarelix—prostate cancer	0.00125	0.00228	CcSEcCtD
Phentolamine—Headache—Degarelix—prostate cancer	0.00123	0.00225	CcSEcCtD
Phentolamine—Nausea—Estradiol valerate/Dienogest—prostate cancer	0.00123	0.00224	CcSEcCtD
Phentolamine—Dizziness—Cabazitaxel—prostate cancer	0.00123	0.00224	CcSEcCtD
Phentolamine—Injection site pain—Doxorubicin—prostate cancer	0.00121	0.00221	CcSEcCtD
Phentolamine—Vomiting—Cabazitaxel—prostate cancer	0.00118	0.00215	CcSEcCtD
Phentolamine—Bradycardia—Mitoxantrone—prostate cancer	0.00117	0.00214	CcSEcCtD
Phentolamine—Hypertension—Goserelin—prostate cancer	0.00117	0.00214	CcSEcCtD
Phentolamine—Nausea—Degarelix—prostate cancer	0.00117	0.00213	CcSEcCtD
Phentolamine—Headache—Cabazitaxel—prostate cancer	0.00116	0.00212	CcSEcCtD
Phentolamine—Gastrointestinal disorder—Ethinyl Estradiol—prostate cancer	0.00116	0.00212	CcSEcCtD
Phentolamine—SIGMAR1—Levonorgestrel—Ethinyl Estradiol—prostate cancer	0.00116	0.0669	CbGdCrCtD
Phentolamine—Chest pain—Goserelin—prostate cancer	0.00115	0.00211	CcSEcCtD
Phentolamine—Flushing—Estradiol—prostate cancer	0.00115	0.00209	CcSEcCtD
Phentolamine—Cardiac disorder—Estradiol—prostate cancer	0.00115	0.00209	CcSEcCtD
Phentolamine—Chest pain—Conjugated Estrogens—prostate cancer	0.00114	0.00209	CcSEcCtD
Phentolamine—Asthenia—Bicalutamide—prostate cancer	0.00114	0.00208	CcSEcCtD
Phentolamine—Pruritus—Bicalutamide—prostate cancer	0.00113	0.00205	CcSEcCtD
Phentolamine—Angiopathy—Estradiol—prostate cancer	0.00112	0.00204	CcSEcCtD
Phentolamine—Mediastinal disorder—Estradiol—prostate cancer	0.00111	0.00203	CcSEcCtD
Phentolamine—Nausea—Cabazitaxel—prostate cancer	0.0011	0.00201	CcSEcCtD
Phentolamine—Gastrointestinal pain—Ethinyl Estradiol—prostate cancer	0.0011	0.00201	CcSEcCtD
Phentolamine—Diarrhoea—Bicalutamide—prostate cancer	0.00109	0.00199	CcSEcCtD
Phentolamine—Nervous system disorder—Goserelin—prostate cancer	0.00109	0.00198	CcSEcCtD
Phentolamine—Tachycardia—Goserelin—prostate cancer	0.00108	0.00197	CcSEcCtD
Phentolamine—Nervous system disorder—Conjugated Estrogens—prostate cancer	0.00107	0.00196	CcSEcCtD
Phentolamine—Tachycardia—Conjugated Estrogens—prostate cancer	0.00107	0.00195	CcSEcCtD
Phentolamine—Abdominal pain—Ethinyl Estradiol—prostate cancer	0.00106	0.00194	CcSEcCtD
Phentolamine—Injection site reaction—Epirubicin—prostate cancer	0.00106	0.00194	CcSEcCtD
Phentolamine—Dizziness—Bicalutamide—prostate cancer	0.00105	0.00192	CcSEcCtD
Phentolamine—Acute coronary syndrome—Etoposide—prostate cancer	0.00105	0.00192	CcSEcCtD
Phentolamine—Orthostatic hypotension—Docetaxel—prostate cancer	0.00105	0.00192	CcSEcCtD
Phentolamine—Abdominal pain upper—Docetaxel—prostate cancer	0.00105	0.00192	CcSEcCtD
Phentolamine—Myocardial infarction—Etoposide—prostate cancer	0.00104	0.00191	CcSEcCtD
Phentolamine—Hypotension—Goserelin—prostate cancer	0.00103	0.00189	CcSEcCtD
Phentolamine—Arrhythmia—Mitoxantrone—prostate cancer	0.00103	0.00187	CcSEcCtD
Phentolamine—Hypotension—Conjugated Estrogens—prostate cancer	0.00102	0.00187	CcSEcCtD
Phentolamine—Orthostatic hypotension—Capecitabine—prostate cancer	0.00102	0.00185	CcSEcCtD
Phentolamine—Abdominal pain upper—Capecitabine—prostate cancer	0.00102	0.00185	CcSEcCtD
Phentolamine—Vomiting—Bicalutamide—prostate cancer	0.00101	0.00184	CcSEcCtD
Phentolamine—Headache—Bicalutamide—prostate cancer	0.000996	0.00182	CcSEcCtD
Phentolamine—Paraesthesia—Goserelin—prostate cancer	0.000994	0.00181	CcSEcCtD
Phentolamine—Paraesthesia—Conjugated Estrogens—prostate cancer	0.000984	0.0018	CcSEcCtD
Phentolamine—Injection site reaction—Doxorubicin—prostate cancer	0.000982	0.00179	CcSEcCtD
Phentolamine—Angina pectoris—Docetaxel—prostate cancer	0.000968	0.00177	CcSEcCtD
Phentolamine—Asthenia—Ethinyl Estradiol—prostate cancer	0.000965	0.00176	CcSEcCtD
Phentolamine—Pruritus—Ethinyl Estradiol—prostate cancer	0.000951	0.00174	CcSEcCtD
Phentolamine—Gastrointestinal disorder—Conjugated Estrogens—prostate cancer	0.000946	0.00173	CcSEcCtD
Phentolamine—Pain—Goserelin—prostate cancer	0.000946	0.00173	CcSEcCtD
Phentolamine—Nausea—Bicalutamide—prostate cancer	0.000945	0.00172	CcSEcCtD
Phentolamine—Pain—Conjugated Estrogens—prostate cancer	0.000937	0.00171	CcSEcCtD
Phentolamine—Angina pectoris—Capecitabine—prostate cancer	0.000937	0.00171	CcSEcCtD
Phentolamine—Hypertension—Estradiol—prostate cancer	0.000928	0.00169	CcSEcCtD
Phentolamine—Diarrhoea—Ethinyl Estradiol—prostate cancer	0.00092	0.00168	CcSEcCtD
Phentolamine—Chest pain—Estradiol—prostate cancer	0.000915	0.00167	CcSEcCtD
Phentolamine—Gastrointestinal pain—Goserelin—prostate cancer	0.000905	0.00165	CcSEcCtD
Phentolamine—Gastrointestinal pain—Conjugated Estrogens—prostate cancer	0.000896	0.00163	CcSEcCtD
Phentolamine—Dizziness—Ethinyl Estradiol—prostate cancer	0.000889	0.00162	CcSEcCtD
Phentolamine—Flushing—Etoposide—prostate cancer	0.000888	0.00162	CcSEcCtD
Phentolamine—Cardiac disorder—Etoposide—prostate cancer	0.000888	0.00162	CcSEcCtD
Phentolamine—Abdominal pain—Goserelin—prostate cancer	0.000875	0.0016	CcSEcCtD
Phentolamine—Acute coronary syndrome—Docetaxel—prostate cancer	0.000873	0.00159	CcSEcCtD
Phentolamine—Myocardial infarction—Docetaxel—prostate cancer	0.000868	0.00158	CcSEcCtD
Phentolamine—Angiopathy—Etoposide—prostate cancer	0.000868	0.00158	CcSEcCtD
Phentolamine—Abdominal pain—Conjugated Estrogens—prostate cancer	0.000866	0.00158	CcSEcCtD
Phentolamine—Hypertension—Mitoxantrone—prostate cancer	0.000865	0.00158	CcSEcCtD
Phentolamine—Mediastinal disorder—Etoposide—prostate cancer	0.000862	0.00157	CcSEcCtD
Phentolamine—Nervous system disorder—Estradiol—prostate cancer	0.00086	0.00157	CcSEcCtD
Phentolamine—Tachycardia—Estradiol—prostate cancer	0.000856	0.00156	CcSEcCtD
Phentolamine—Vomiting—Ethinyl Estradiol—prostate cancer	0.000855	0.00156	CcSEcCtD
Phentolamine—Chest pain—Mitoxantrone—prostate cancer	0.000853	0.00156	CcSEcCtD
Phentolamine—Acute coronary syndrome—Capecitabine—prostate cancer	0.000845	0.00154	CcSEcCtD
Phentolamine—Headache—Ethinyl Estradiol—prostate cancer	0.000842	0.00154	CcSEcCtD
Phentolamine—Myocardial infarction—Capecitabine—prostate cancer	0.000841	0.00153	CcSEcCtD
Phentolamine—Nausea—Ethinyl Estradiol—prostate cancer	0.000799	0.00146	CcSEcCtD
Phentolamine—Tachycardia—Mitoxantrone—prostate cancer	0.000798	0.00146	CcSEcCtD
Phentolamine—Asthenia—Goserelin—prostate cancer	0.000794	0.00145	CcSEcCtD
Phentolamine—Paraesthesia—Estradiol—prostate cancer	0.000788	0.00144	CcSEcCtD
Phentolamine—Asthenia—Conjugated Estrogens—prostate cancer	0.000786	0.00143	CcSEcCtD
Phentolamine—Bradycardia—Capecitabine—prostate cancer	0.000784	0.00143	CcSEcCtD
Phentolamine—Pruritus—Goserelin—prostate cancer	0.000783	0.00143	CcSEcCtD
Phentolamine—Pruritus—Conjugated Estrogens—prostate cancer	0.000775	0.00141	CcSEcCtD
Phentolamine—Hypotension—Mitoxantrone—prostate cancer	0.000764	0.00139	CcSEcCtD
Phentolamine—Gastrointestinal disorder—Estradiol—prostate cancer	0.000757	0.00138	CcSEcCtD
Phentolamine—Diarrhoea—Goserelin—prostate cancer	0.000757	0.00138	CcSEcCtD
Phentolamine—Acute coronary syndrome—Prednisone—prostate cancer	0.000753	0.00137	CcSEcCtD
Phentolamine—Pain—Estradiol—prostate cancer	0.00075	0.00137	CcSEcCtD
Phentolamine—Diarrhoea—Conjugated Estrogens—prostate cancer	0.00075	0.00137	CcSEcCtD
Phentolamine—Myocardial infarction—Prednisone—prostate cancer	0.000749	0.00137	CcSEcCtD
Phentolamine—Flushing—Docetaxel—prostate cancer	0.000738	0.00135	CcSEcCtD
Phentolamine—Cardiac disorder—Docetaxel—prostate cancer	0.000738	0.00135	CcSEcCtD
Phentolamine—Paraesthesia—Mitoxantrone—prostate cancer	0.000734	0.00134	CcSEcCtD
Phentolamine—Dizziness—Goserelin—prostate cancer	0.000732	0.00133	CcSEcCtD
Phentolamine—Dizziness—Conjugated Estrogens—prostate cancer	0.000725	0.00132	CcSEcCtD
Phentolamine—Angiopathy—Docetaxel—prostate cancer	0.000721	0.00132	CcSEcCtD
Phentolamine—Hypertension—Etoposide—prostate cancer	0.000719	0.00131	CcSEcCtD
Phentolamine—Gastrointestinal pain—Estradiol—prostate cancer	0.000717	0.00131	CcSEcCtD
Phentolamine—Mediastinal disorder—Docetaxel—prostate cancer	0.000717	0.00131	CcSEcCtD
Phentolamine—Cardiac disorder—Capecitabine—prostate cancer	0.000715	0.0013	CcSEcCtD
Phentolamine—Flushing—Capecitabine—prostate cancer	0.000715	0.0013	CcSEcCtD
Phentolamine—Arrhythmia—Docetaxel—prostate cancer	0.00071	0.0013	CcSEcCtD
Phentolamine—Chest pain—Etoposide—prostate cancer	0.000709	0.00129	CcSEcCtD
Phentolamine—Abdominal pain upper—Epirubicin—prostate cancer	0.000708	0.00129	CcSEcCtD
Phentolamine—Orthostatic hypotension—Epirubicin—prostate cancer	0.000708	0.00129	CcSEcCtD
Phentolamine—Vomiting—Goserelin—prostate cancer	0.000703	0.00128	CcSEcCtD
Phentolamine—Pain—Mitoxantrone—prostate cancer	0.000699	0.00127	CcSEcCtD
Phentolamine—Angiopathy—Capecitabine—prostate cancer	0.000699	0.00127	CcSEcCtD
Phentolamine—Bradycardia—Prednisone—prostate cancer	0.000698	0.00127	CcSEcCtD
Phentolamine—Vomiting—Conjugated Estrogens—prostate cancer	0.000697	0.00127	CcSEcCtD
Phentolamine—Mediastinal disorder—Capecitabine—prostate cancer	0.000694	0.00127	CcSEcCtD
Phentolamine—Abdominal pain—Estradiol—prostate cancer	0.000693	0.00126	CcSEcCtD
Phentolamine—Headache—Goserelin—prostate cancer	0.000693	0.00126	CcSEcCtD
Phentolamine—Arrhythmia—Capecitabine—prostate cancer	0.000688	0.00125	CcSEcCtD
Phentolamine—Headache—Conjugated Estrogens—prostate cancer	0.000687	0.00125	CcSEcCtD
Phentolamine—Gastrointestinal pain—Mitoxantrone—prostate cancer	0.000668	0.00122	CcSEcCtD
Phentolamine—Tachycardia—Etoposide—prostate cancer	0.000663	0.00121	CcSEcCtD
Phentolamine—Nausea—Goserelin—prostate cancer	0.000657	0.0012	CcSEcCtD
Phentolamine—Orthostatic hypotension—Doxorubicin—prostate cancer	0.000655	0.0012	CcSEcCtD
Phentolamine—Abdominal pain upper—Doxorubicin—prostate cancer	0.000655	0.0012	CcSEcCtD
Phentolamine—Angina pectoris—Epirubicin—prostate cancer	0.000653	0.00119	CcSEcCtD
Phentolamine—Nausea—Conjugated Estrogens—prostate cancer	0.000651	0.00119	CcSEcCtD
Phentolamine—Abdominal pain—Mitoxantrone—prostate cancer	0.000646	0.00118	CcSEcCtD
Phentolamine—Flushing—Prednisone—prostate cancer	0.000636	0.00116	CcSEcCtD
Phentolamine—Hypotension—Etoposide—prostate cancer	0.000635	0.00116	CcSEcCtD
Phentolamine—Asthenia—Estradiol—prostate cancer	0.000629	0.00115	CcSEcCtD
Phentolamine—Angiopathy—Prednisone—prostate cancer	0.000622	0.00113	CcSEcCtD
Phentolamine—Pruritus—Estradiol—prostate cancer	0.000621	0.00113	CcSEcCtD
Phentolamine—Arrhythmia—Prednisone—prostate cancer	0.000613	0.00112	CcSEcCtD
Phentolamine—Paraesthesia—Etoposide—prostate cancer	0.00061	0.00111	CcSEcCtD
Phentolamine—Angina pectoris—Doxorubicin—prostate cancer	0.000604	0.0011	CcSEcCtD
Phentolamine—Diarrhoea—Estradiol—prostate cancer	0.0006	0.00109	CcSEcCtD
Phentolamine—Hypertension—Docetaxel—prostate cancer	0.000598	0.00109	CcSEcCtD
Phentolamine—Chest pain—Docetaxel—prostate cancer	0.000589	0.00108	CcSEcCtD
Phentolamine—Gastrointestinal disorder—Etoposide—prostate cancer	0.000587	0.00107	CcSEcCtD
Phentolamine—Asthenia—Mitoxantrone—prostate cancer	0.000586	0.00107	CcSEcCtD
Phentolamine—Pain—Etoposide—prostate cancer	0.000581	0.00106	CcSEcCtD
Phentolamine—Dizziness—Estradiol—prostate cancer	0.00058	0.00106	CcSEcCtD
Phentolamine—Hypertension—Capecitabine—prostate cancer	0.000579	0.00106	CcSEcCtD
Phentolamine—Chest pain—Capecitabine—prostate cancer	0.000571	0.00104	CcSEcCtD
Phentolamine—Diarrhoea—Mitoxantrone—prostate cancer	0.000559	0.00102	CcSEcCtD
Phentolamine—Vomiting—Estradiol—prostate cancer	0.000558	0.00102	CcSEcCtD
Phentolamine—Gastrointestinal pain—Etoposide—prostate cancer	0.000556	0.00101	CcSEcCtD
Phentolamine—Nervous system disorder—Docetaxel—prostate cancer	0.000554	0.00101	CcSEcCtD
Phentolamine—Tachycardia—Docetaxel—prostate cancer	0.000551	0.00101	CcSEcCtD
Phentolamine—Headache—Estradiol—prostate cancer	0.000549	0.001	CcSEcCtD
Phentolamine—Bradycardia—Epirubicin—prostate cancer	0.000546	0.000996	CcSEcCtD
Phentolamine—Abdominal pain—Etoposide—prostate cancer	0.000537	0.00098	CcSEcCtD
Phentolamine—Nervous system disorder—Capecitabine—prostate cancer	0.000536	0.000979	CcSEcCtD
Phentolamine—Tachycardia—Capecitabine—prostate cancer	0.000534	0.000974	CcSEcCtD
Phentolamine—Hypotension—Docetaxel—prostate cancer	0.000528	0.000963	CcSEcCtD
Phentolamine—Nausea—Estradiol—prostate cancer	0.000521	0.00095	CcSEcCtD
Phentolamine—Vomiting—Mitoxantrone—prostate cancer	0.00052	0.000948	CcSEcCtD
Phentolamine—Hypertension—Prednisone—prostate cancer	0.000515	0.00094	CcSEcCtD
Phentolamine—Headache—Mitoxantrone—prostate cancer	0.000512	0.000934	CcSEcCtD
Phentolamine—Hypotension—Capecitabine—prostate cancer	0.000511	0.000932	CcSEcCtD
Phentolamine—Paraesthesia—Docetaxel—prostate cancer	0.000507	0.000925	CcSEcCtD
Phentolamine—Bradycardia—Doxorubicin—prostate cancer	0.000505	0.000922	CcSEcCtD
Phentolamine—Flushing—Epirubicin—prostate cancer	0.000498	0.000908	CcSEcCtD
Phentolamine—Cardiac disorder—Epirubicin—prostate cancer	0.000498	0.000908	CcSEcCtD
Phentolamine—Paraesthesia—Capecitabine—prostate cancer	0.000491	0.000896	CcSEcCtD
Phentolamine—Gastrointestinal disorder—Docetaxel—prostate cancer	0.000488	0.00089	CcSEcCtD
Phentolamine—Asthenia—Etoposide—prostate cancer	0.000488	0.00089	CcSEcCtD
Phentolamine—Angiopathy—Epirubicin—prostate cancer	0.000487	0.000888	CcSEcCtD
Phentolamine—Nausea—Mitoxantrone—prostate cancer	0.000485	0.000886	CcSEcCtD
Phentolamine—Mediastinal disorder—Epirubicin—prostate cancer	0.000483	0.000882	CcSEcCtD
Phentolamine—Pain—Docetaxel—prostate cancer	0.000483	0.000881	CcSEcCtD
Phentolamine—Pruritus—Etoposide—prostate cancer	0.000481	0.000877	CcSEcCtD
Phentolamine—Arrhythmia—Epirubicin—prostate cancer	0.000479	0.000874	CcSEcCtD
Phentolamine—Nervous system disorder—Prednisone—prostate cancer	0.000478	0.000872	CcSEcCtD
Phentolamine—Tachycardia—Prednisone—prostate cancer	0.000476	0.000867	CcSEcCtD
Phentolamine—Gastrointestinal disorder—Capecitabine—prostate cancer	0.000472	0.000861	CcSEcCtD
Phentolamine—Pain—Capecitabine—prostate cancer	0.000468	0.000853	CcSEcCtD
Phentolamine—Diarrhoea—Etoposide—prostate cancer	0.000465	0.000848	CcSEcCtD
Phentolamine—Gastrointestinal pain—Docetaxel—prostate cancer	0.000462	0.000843	CcSEcCtD
Phentolamine—Cardiac disorder—Doxorubicin—prostate cancer	0.000461	0.00084	CcSEcCtD
Phentolamine—Flushing—Doxorubicin—prostate cancer	0.000461	0.00084	CcSEcCtD
Phentolamine—Angiopathy—Doxorubicin—prostate cancer	0.00045	0.000821	CcSEcCtD
Phentolamine—Dizziness—Etoposide—prostate cancer	0.00045	0.00082	CcSEcCtD
Phentolamine—Gastrointestinal pain—Capecitabine—prostate cancer	0.000447	0.000816	CcSEcCtD
Phentolamine—Mediastinal disorder—Doxorubicin—prostate cancer	0.000447	0.000816	CcSEcCtD
Phentolamine—Abdominal pain—Docetaxel—prostate cancer	0.000447	0.000815	CcSEcCtD
Phentolamine—Arrhythmia—Doxorubicin—prostate cancer	0.000443	0.000809	CcSEcCtD
Phentolamine—Paraesthesia—Prednisone—prostate cancer	0.000438	0.000798	CcSEcCtD
Phentolamine—Abdominal pain—Capecitabine—prostate cancer	0.000432	0.000789	CcSEcCtD
Phentolamine—Vomiting—Etoposide—prostate cancer	0.000432	0.000788	CcSEcCtD
Phentolamine—Headache—Etoposide—prostate cancer	0.000426	0.000777	CcSEcCtD
Phentolamine—Asthenia—Docetaxel—prostate cancer	0.000405	0.000739	CcSEcCtD
Phentolamine—Nausea—Etoposide—prostate cancer	0.000404	0.000737	CcSEcCtD
Phentolamine—Hypertension—Epirubicin—prostate cancer	0.000403	0.000735	CcSEcCtD
Phentolamine—Pruritus—Docetaxel—prostate cancer	0.0004	0.000729	CcSEcCtD
Phentolamine—Gastrointestinal pain—Prednisone—prostate cancer	0.000398	0.000727	CcSEcCtD
Phentolamine—Chest pain—Epirubicin—prostate cancer	0.000398	0.000725	CcSEcCtD
Phentolamine—Asthenia—Capecitabine—prostate cancer	0.000392	0.000716	CcSEcCtD
Phentolamine—Pruritus—Capecitabine—prostate cancer	0.000387	0.000706	CcSEcCtD
Phentolamine—Diarrhoea—Docetaxel—prostate cancer	0.000387	0.000705	CcSEcCtD
Phentolamine—Abdominal pain—Prednisone—prostate cancer	0.000385	0.000703	CcSEcCtD
Phentolamine—Diarrhoea—Capecitabine—prostate cancer	0.000374	0.000683	CcSEcCtD
Phentolamine—Nervous system disorder—Epirubicin—prostate cancer	0.000374	0.000682	CcSEcCtD
Phentolamine—Dizziness—Docetaxel—prostate cancer	0.000374	0.000681	CcSEcCtD
Phentolamine—Hypertension—Doxorubicin—prostate cancer	0.000373	0.00068	CcSEcCtD
Phentolamine—Tachycardia—Epirubicin—prostate cancer	0.000372	0.000678	CcSEcCtD
Phentolamine—Chest pain—Doxorubicin—prostate cancer	0.000368	0.000671	CcSEcCtD
Phentolamine—Dizziness—Capecitabine—prostate cancer	0.000362	0.00066	CcSEcCtD
Phentolamine—Vomiting—Docetaxel—prostate cancer	0.000359	0.000655	CcSEcCtD
Phentolamine—Hypotension—Epirubicin—prostate cancer	0.000356	0.00065	CcSEcCtD
Phentolamine—Headache—Docetaxel—prostate cancer	0.000354	0.000646	CcSEcCtD
Phentolamine—Asthenia—Prednisone—prostate cancer	0.00035	0.000638	CcSEcCtD
Phentolamine—Vomiting—Capecitabine—prostate cancer	0.000348	0.000634	CcSEcCtD
Phentolamine—Nervous system disorder—Doxorubicin—prostate cancer	0.000346	0.000631	CcSEcCtD
Phentolamine—Pruritus—Prednisone—prostate cancer	0.000345	0.000629	CcSEcCtD
Phentolamine—Tachycardia—Doxorubicin—prostate cancer	0.000344	0.000628	CcSEcCtD
Phentolamine—Headache—Capecitabine—prostate cancer	0.000343	0.000625	CcSEcCtD
Phentolamine—Paraesthesia—Epirubicin—prostate cancer	0.000342	0.000624	CcSEcCtD
Phentolamine—Nausea—Docetaxel—prostate cancer	0.000336	0.000612	CcSEcCtD
Phentolamine—Diarrhoea—Prednisone—prostate cancer	0.000333	0.000608	CcSEcCtD
Phentolamine—Hypotension—Doxorubicin—prostate cancer	0.000329	0.000601	CcSEcCtD
Phentolamine—Gastrointestinal disorder—Epirubicin—prostate cancer	0.000329	0.0006	CcSEcCtD
Phentolamine—Pain—Epirubicin—prostate cancer	0.000326	0.000594	CcSEcCtD
Phentolamine—Nausea—Capecitabine—prostate cancer	0.000325	0.000593	CcSEcCtD
Phentolamine—Dizziness—Prednisone—prostate cancer	0.000322	0.000588	CcSEcCtD
Phentolamine—Paraesthesia—Doxorubicin—prostate cancer	0.000317	0.000578	CcSEcCtD
Phentolamine—Gastrointestinal pain—Epirubicin—prostate cancer	0.000312	0.000568	CcSEcCtD
Phentolamine—Vomiting—Prednisone—prostate cancer	0.00031	0.000565	CcSEcCtD
Phentolamine—Headache—Prednisone—prostate cancer	0.000305	0.000557	CcSEcCtD
Phentolamine—Gastrointestinal disorder—Doxorubicin—prostate cancer	0.000304	0.000555	CcSEcCtD
Phentolamine—Pain—Doxorubicin—prostate cancer	0.000302	0.00055	CcSEcCtD
Phentolamine—Abdominal pain—Epirubicin—prostate cancer	0.000301	0.000549	CcSEcCtD
Phentolamine—Nausea—Prednisone—prostate cancer	0.000289	0.000528	CcSEcCtD
Phentolamine—Gastrointestinal pain—Doxorubicin—prostate cancer	0.000288	0.000526	CcSEcCtD
Phentolamine—Abdominal pain—Doxorubicin—prostate cancer	0.000279	0.000508	CcSEcCtD
Phentolamine—Asthenia—Epirubicin—prostate cancer	0.000273	0.000499	CcSEcCtD
Phentolamine—Pruritus—Epirubicin—prostate cancer	0.00027	0.000492	CcSEcCtD
Phentolamine—Diarrhoea—Epirubicin—prostate cancer	0.000261	0.000476	CcSEcCtD
Phentolamine—Asthenia—Doxorubicin—prostate cancer	0.000253	0.000461	CcSEcCtD
Phentolamine—Dizziness—Epirubicin—prostate cancer	0.000252	0.00046	CcSEcCtD
Phentolamine—Pruritus—Doxorubicin—prostate cancer	0.000249	0.000455	CcSEcCtD
Phentolamine—Vomiting—Epirubicin—prostate cancer	0.000242	0.000442	CcSEcCtD
Phentolamine—Diarrhoea—Doxorubicin—prostate cancer	0.000241	0.00044	CcSEcCtD
Phentolamine—Headache—Epirubicin—prostate cancer	0.000239	0.000435	CcSEcCtD
Phentolamine—Dizziness—Doxorubicin—prostate cancer	0.000233	0.000425	CcSEcCtD
Phentolamine—Nausea—Epirubicin—prostate cancer	0.000226	0.000413	CcSEcCtD
Phentolamine—Vomiting—Doxorubicin—prostate cancer	0.000224	0.000409	CcSEcCtD
Phentolamine—Headache—Doxorubicin—prostate cancer	0.000221	0.000403	CcSEcCtD
Phentolamine—Nausea—Doxorubicin—prostate cancer	0.000209	0.000382	CcSEcCtD
Phentolamine—ADRA1A—Signaling Pathways—ESR1—prostate cancer	1.6e-05	8e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—HIF1A—prostate cancer	1.59e-05	7.98e-05	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling by GPCR—KRAS—prostate cancer	1.59e-05	7.97e-05	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling Pathways—ERBB2—prostate cancer	1.59e-05	7.97e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Metabolism—INS—prostate cancer	1.59e-05	7.96e-05	CbGpPWpGaD
Phentolamine—ADRA2C—Metabolism—PIK3CB—prostate cancer	1.58e-05	7.93e-05	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—IGF1—prostate cancer	1.58e-05	7.92e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Hemostasis—AKT1—prostate cancer	1.58e-05	7.91e-05	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—CREBBP—prostate cancer	1.58e-05	7.9e-05	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling by GPCR—EGFR—prostate cancer	1.57e-05	7.88e-05	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling Pathways—PIK3CB—prostate cancer	1.57e-05	7.86e-05	CbGpPWpGaD
Phentolamine—ADRA2C—Metabolism—PTGS2—prostate cancer	1.57e-05	7.86e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—BAD—prostate cancer	1.56e-05	7.81e-05	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—IGF1—prostate cancer	1.56e-05	7.8e-05	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling Pathways—FGF2—prostate cancer	1.56e-05	7.8e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Metabolism—CREBBP—prostate cancer	1.56e-05	7.79e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—LEP—prostate cancer	1.55e-05	7.79e-05	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling by GPCR—EGFR—prostate cancer	1.55e-05	7.76e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—CAV1—prostate cancer	1.54e-05	7.72e-05	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling Pathways—NOS3—prostate cancer	1.53e-05	7.69e-05	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—MAP2K1—prostate cancer	1.53e-05	7.66e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—KDR—prostate cancer	1.52e-05	7.63e-05	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—PIK3CD—prostate cancer	1.52e-05	7.61e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—APC—prostate cancer	1.51e-05	7.56e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—PIK3CG—prostate cancer	1.51e-05	7.56e-05	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling Pathways—CXCL8—prostate cancer	1.51e-05	7.56e-05	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—MAP2K1—prostate cancer	1.5e-05	7.54e-05	CbGpPWpGaD
Phentolamine—ADRA2C—GPCR downstream signaling—PIK3CA—prostate cancer	1.5e-05	7.53e-05	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—SERPINE1—prostate cancer	1.5e-05	7.52e-05	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—PIK3CD—prostate cancer	1.49e-05	7.49e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—EGF—prostate cancer	1.49e-05	7.48e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—IRS1—prostate cancer	1.49e-05	7.48e-05	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling Pathways—JAK2—prostate cancer	1.49e-05	7.47e-05	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling by GPCR—KRAS—prostate cancer	1.49e-05	7.45e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—ESR1—prostate cancer	1.48e-05	7.43e-05	CbGpPWpGaD
Phentolamine—ADRA1B—GPCR downstream signaling—PIK3CA—prostate cancer	1.48e-05	7.42e-05	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—SERPINE1—prostate cancer	1.48e-05	7.4e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Metabolism—PIK3CD—prostate cancer	1.47e-05	7.39e-05	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling Pathways—CDKN1B—prostate cancer	1.47e-05	7.38e-05	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling by GPCR—KRAS—prostate cancer	1.46e-05	7.33e-05	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling by GPCR—PIK3CA—prostate cancer	1.46e-05	7.32e-05	CbGpPWpGaD
Phentolamine—ADRA1D—GPCR downstream signaling—AKT1—prostate cancer	1.46e-05	7.3e-05	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling Pathways—MDM2—prostate cancer	1.46e-05	7.3e-05	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—FGF2—prostate cancer	1.45e-05	7.28e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—GSK3B—prostate cancer	1.45e-05	7.26e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—BAD—prostate cancer	1.45e-05	7.26e-05	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling Pathways—CASP3—prostate cancer	1.44e-05	7.23e-05	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling Pathways—IL2—prostate cancer	1.44e-05	7.22e-05	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling Pathways—ERBB2—prostate cancer	1.44e-05	7.19e-05	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling by GPCR—IL6—prostate cancer	1.43e-05	7.18e-05	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—NOS3—prostate cancer	1.43e-05	7.18e-05	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—FGF2—prostate cancer	1.43e-05	7.17e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—INS—prostate cancer	1.43e-05	7.16e-05	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling Pathways—PIK3CB—prostate cancer	1.42e-05	7.1e-05	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—NOS3—prostate cancer	1.41e-05	7.07e-05	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling Pathways—CCND1—prostate cancer	1.4e-05	7.04e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—APC—prostate cancer	1.4e-05	7.03e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—PIK3CG—prostate cancer	1.4e-05	7.03e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—CREBBP—prostate cancer	1.4e-05	7.01e-05	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—JAK2—prostate cancer	1.39e-05	6.98e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Metabolism—NOS3—prostate cancer	1.39e-05	6.98e-05	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling Pathways—CTNNB1—prostate cancer	1.39e-05	6.97e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—EGF—prostate cancer	1.39e-05	6.95e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—IRS1—prostate cancer	1.39e-05	6.95e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—IGF1—prostate cancer	1.38e-05	6.93e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling by GPCR—EGFR—prostate cancer	1.38e-05	6.89e-05	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—JAK2—prostate cancer	1.37e-05	6.87e-05	CbGpPWpGaD
Phentolamine—ADRA2C—Metabolism—PTEN—prostate cancer	1.37e-05	6.85e-05	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling by GPCR—PIK3CA—prostate cancer	1.37e-05	6.84e-05	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling Pathways—MMP9—prostate cancer	1.36e-05	6.83e-05	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling Pathways—CXCL8—prostate cancer	1.36e-05	6.82e-05	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—MDM2—prostate cancer	1.36e-05	6.81e-05	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling Pathways—CDKN1A—prostate cancer	1.36e-05	6.81e-05	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling Pathways—PTEN—prostate cancer	1.36e-05	6.79e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—GSK3B—prostate cancer	1.35e-05	6.74e-05	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling by GPCR—PIK3CA—prostate cancer	1.34e-05	6.73e-05	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—ERBB2—prostate cancer	1.34e-05	6.72e-05	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—MDM2—prostate cancer	1.34e-05	6.71e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—MAP2K1—prostate cancer	1.34e-05	6.69e-05	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling Pathways—CDKN1B—prostate cancer	1.33e-05	6.66e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—INS—prostate cancer	1.33e-05	6.65e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—PIK3CD—prostate cancer	1.33e-05	6.65e-05	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—PIK3CB—prostate cancer	1.32e-05	6.63e-05	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling by GPCR—AKT1—prostate cancer	1.32e-05	6.63e-05	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—ERBB2—prostate cancer	1.32e-05	6.61e-05	CbGpPWpGaD
Phentolamine—ADRA2B—GPCR downstream signaling—AKT1—prostate cancer	1.32e-05	6.59e-05	CbGpPWpGaD
Phentolamine—ADRA1A—GPCR downstream signaling—PIK3CA—prostate cancer	1.31e-05	6.59e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—SERPINE1—prostate cancer	1.31e-05	6.58e-05	CbGpPWpGaD
Phentolamine—ADRA2C—Metabolism—EP300—prostate cancer	1.3e-05	6.53e-05	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling Pathways—CASP3—prostate cancer	1.3e-05	6.53e-05	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—PIK3CB—prostate cancer	1.3e-05	6.53e-05	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling Pathways—IL2—prostate cancer	1.3e-05	6.52e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—CREBBP—prostate cancer	1.3e-05	6.52e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling by GPCR—KRAS—prostate cancer	1.3e-05	6.51e-05	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling by GPCR—IL6—prostate cancer	1.29e-05	6.49e-05	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling Pathways—EP300—prostate cancer	1.29e-05	6.48e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Metabolism—PIK3CB—prostate cancer	1.29e-05	6.44e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—IGF1—prostate cancer	1.28e-05	6.44e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling by GPCR—EGFR—prostate cancer	1.28e-05	6.4e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Metabolism—PTGS2—prostate cancer	1.27e-05	6.38e-05	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—CXCL8—prostate cancer	1.27e-05	6.37e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—FGF2—prostate cancer	1.27e-05	6.37e-05	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling Pathways—CCND1—prostate cancer	1.27e-05	6.35e-05	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling Pathways—SRC—prostate cancer	1.26e-05	6.3e-05	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling Pathways—CTNNB1—prostate cancer	1.26e-05	6.29e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—NOS3—prostate cancer	1.25e-05	6.28e-05	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—CXCL8—prostate cancer	1.25e-05	6.27e-05	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—CDKN1B—prostate cancer	1.24e-05	6.22e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—MAP2K1—prostate cancer	1.24e-05	6.22e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—PIK3CD—prostate cancer	1.23e-05	6.18e-05	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling Pathways—MMP9—prostate cancer	1.23e-05	6.17e-05	CbGpPWpGaD
Phentolamine—ADRA2C—GPCR downstream signaling—AKT1—prostate cancer	1.23e-05	6.15e-05	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling Pathways—CDKN1A—prostate cancer	1.23e-05	6.15e-05	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling Pathways—VEGFA—prostate cancer	1.22e-05	6.14e-05	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling Pathways—PTEN—prostate cancer	1.22e-05	6.13e-05	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—CDKN1B—prostate cancer	1.22e-05	6.12e-05	CbGpPWpGaD
Phentolamine—ADRA2A—GPCR downstream signaling—PIK3CA—prostate cancer	1.22e-05	6.12e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—SERPINE1—prostate cancer	1.22e-05	6.11e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—JAK2—prostate cancer	1.22e-05	6.1e-05	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—CASP3—prostate cancer	1.22e-05	6.1e-05	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—IL2—prostate cancer	1.22e-05	6.09e-05	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling Pathways—STAT3—prostate cancer	1.21e-05	6.08e-05	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling by GPCR—IL6—prostate cancer	1.21e-05	6.06e-05	CbGpPWpGaD
Phentolamine—ADRA1B—GPCR downstream signaling—AKT1—prostate cancer	1.21e-05	6.06e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling by GPCR—KRAS—prostate cancer	1.21e-05	6.05e-05	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—CASP3—prostate cancer	1.2e-05	6e-05	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—IL2—prostate cancer	1.2e-05	5.99e-05	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling by GPCR—AKT1—prostate cancer	1.19e-05	5.98e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling by GPCR—PIK3CA—prostate cancer	1.19e-05	5.98e-05	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling by GPCR—IL6—prostate cancer	1.19e-05	5.96e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—MDM2—prostate cancer	1.19e-05	5.96e-05	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—CCND1—prostate cancer	1.18e-05	5.94e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—FGF2—prostate cancer	1.18e-05	5.92e-05	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—CTNNB1—prostate cancer	1.17e-05	5.88e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—ERBB2—prostate cancer	1.17e-05	5.87e-05	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling Pathways—EP300—prostate cancer	1.17e-05	5.85e-05	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—CCND1—prostate cancer	1.17e-05	5.84e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—NOS3—prostate cancer	1.16e-05	5.83e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—PIK3CB—prostate cancer	1.16e-05	5.8e-05	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—CTNNB1—prostate cancer	1.15e-05	5.79e-05	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—MMP9—prostate cancer	1.15e-05	5.76e-05	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—CDKN1A—prostate cancer	1.15e-05	5.74e-05	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—PTEN—prostate cancer	1.14e-05	5.73e-05	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling Pathways—SRC—prostate cancer	1.14e-05	5.69e-05	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—MMP9—prostate cancer	1.13e-05	5.67e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—JAK2—prostate cancer	1.13e-05	5.67e-05	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—CDKN1A—prostate cancer	1.13e-05	5.65e-05	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling Pathways—MYC—prostate cancer	1.13e-05	5.65e-05	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—PTEN—prostate cancer	1.13e-05	5.64e-05	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling Pathways—TGFB1—prostate cancer	1.12e-05	5.63e-05	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling by GPCR—AKT1—prostate cancer	1.12e-05	5.59e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—CXCL8—prostate cancer	1.11e-05	5.57e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Metabolism—PTEN—prostate cancer	1.11e-05	5.57e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling by GPCR—PIK3CA—prostate cancer	1.11e-05	5.56e-05	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling Pathways—VEGFA—prostate cancer	1.11e-05	5.54e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—MDM2—prostate cancer	1.1e-05	5.54e-05	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling Pathways—EGFR—prostate cancer	1.1e-05	5.52e-05	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling by GPCR—AKT1—prostate cancer	1.1e-05	5.5e-05	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling Pathways—STAT3—prostate cancer	1.09e-05	5.49e-05	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—EP300—prostate cancer	1.09e-05	5.46e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—ERBB2—prostate cancer	1.09e-05	5.46e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—CDKN1B—prostate cancer	1.09e-05	5.44e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—PIK3CB—prostate cancer	1.07e-05	5.39e-05	CbGpPWpGaD
Phentolamine—ADRA1A—GPCR downstream signaling—AKT1—prostate cancer	1.07e-05	5.38e-05	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—EP300—prostate cancer	1.07e-05	5.38e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—CASP3—prostate cancer	1.06e-05	5.33e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—IL2—prostate cancer	1.06e-05	5.32e-05	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—SRC—prostate cancer	1.06e-05	5.31e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Metabolism—EP300—prostate cancer	1.06e-05	5.31e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling by GPCR—IL6—prostate cancer	1.06e-05	5.3e-05	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—SRC—prostate cancer	1.04e-05	5.23e-05	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling Pathways—KRAS—prostate cancer	1.04e-05	5.22e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—CCND1—prostate cancer	1.04e-05	5.19e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—CXCL8—prostate cancer	1.03e-05	5.18e-05	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—VEGFA—prostate cancer	1.03e-05	5.17e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—CTNNB1—prostate cancer	1.03e-05	5.14e-05	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—STAT3—prostate cancer	1.02e-05	5.12e-05	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling Pathways—MYC—prostate cancer	1.02e-05	5.1e-05	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—VEGFA—prostate cancer	1.02e-05	5.09e-05	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling Pathways—TGFB1—prostate cancer	1.01e-05	5.08e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—CDKN1B—prostate cancer	1.01e-05	5.05e-05	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—STAT3—prostate cancer	1.01e-05	5.04e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—MMP9—prostate cancer	1.01e-05	5.04e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—CDKN1A—prostate cancer	1e-05	5.02e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—PTEN—prostate cancer	1e-05	5.01e-05	CbGpPWpGaD
Phentolamine—ADRA2A—GPCR downstream signaling—AKT1—prostate cancer	9.98e-06	5e-05	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling Pathways—EGFR—prostate cancer	9.95e-06	4.99e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—CASP3—prostate cancer	9.89e-06	4.95e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—IL2—prostate cancer	9.87e-06	4.95e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling by GPCR—IL6—prostate cancer	9.82e-06	4.92e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling by GPCR—AKT1—prostate cancer	9.75e-06	4.89e-05	CbGpPWpGaD
Phentolamine—ADRA2C—Metabolism—PIK3CA—prostate cancer	9.65e-06	4.83e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—CCND1—prostate cancer	9.62e-06	4.82e-05	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling Pathways—PIK3CA—prostate cancer	9.57e-06	4.79e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—EP300—prostate cancer	9.53e-06	4.78e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—CTNNB1—prostate cancer	9.53e-06	4.77e-05	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—MYC—prostate cancer	9.5e-06	4.76e-05	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—TGFB1—prostate cancer	9.48e-06	4.75e-05	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling Pathways—KRAS—prostate cancer	9.4e-06	4.71e-05	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—MYC—prostate cancer	9.35e-06	4.69e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—MMP9—prostate cancer	9.34e-06	4.68e-05	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—TGFB1—prostate cancer	9.33e-06	4.67e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—CDKN1A—prostate cancer	9.31e-06	4.66e-05	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—EGFR—prostate cancer	9.3e-06	4.66e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—PTEN—prostate cancer	9.29e-06	4.65e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—SRC—prostate cancer	9.27e-06	4.64e-05	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling Pathways—TP53—prostate cancer	9.25e-06	4.64e-05	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—EGFR—prostate cancer	9.15e-06	4.58e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling by GPCR—AKT1—prostate cancer	9.06e-06	4.54e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—VEGFA—prostate cancer	9.03e-06	4.52e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—STAT3—prostate cancer	8.94e-06	4.48e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—EP300—prostate cancer	8.86e-06	4.44e-05	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—KRAS—prostate cancer	8.78e-06	4.4e-05	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—KRAS—prostate cancer	8.64e-06	4.33e-05	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling Pathways—PIK3CA—prostate cancer	8.64e-06	4.33e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—SRC—prostate cancer	8.61e-06	4.32e-05	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling Pathways—IL6—prostate cancer	8.47e-06	4.24e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—VEGFA—prostate cancer	8.39e-06	4.2e-05	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling Pathways—TP53—prostate cancer	8.36e-06	4.19e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—MYC—prostate cancer	8.31e-06	4.16e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—STAT3—prostate cancer	8.31e-06	4.16e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—TGFB1—prostate cancer	8.29e-06	4.15e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—EGFR—prostate cancer	8.13e-06	4.07e-05	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—PIK3CA—prostate cancer	8.07e-06	4.04e-05	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—PIK3CA—prostate cancer	7.94e-06	3.98e-05	CbGpPWpGaD
Phentolamine—ADRA2C—Metabolism—AKT1—prostate cancer	7.88e-06	3.95e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Metabolism—PIK3CA—prostate cancer	7.84e-06	3.93e-05	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling Pathways—AKT1—prostate cancer	7.81e-06	3.92e-05	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—TP53—prostate cancer	7.8e-06	3.91e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—MYC—prostate cancer	7.72e-06	3.87e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—TGFB1—prostate cancer	7.7e-06	3.86e-05	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—TP53—prostate cancer	7.68e-06	3.85e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—KRAS—prostate cancer	7.68e-06	3.85e-05	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling Pathways—IL6—prostate cancer	7.65e-06	3.83e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—EGFR—prostate cancer	7.55e-06	3.78e-05	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—IL6—prostate cancer	7.14e-06	3.58e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—KRAS—prostate cancer	7.13e-06	3.57e-05	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling Pathways—AKT1—prostate cancer	7.06e-06	3.53e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—PIK3CA—prostate cancer	7.05e-06	3.53e-05	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—IL6—prostate cancer	7.03e-06	3.52e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—TP53—prostate cancer	6.82e-06	3.42e-05	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—AKT1—prostate cancer	6.59e-06	3.3e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—PIK3CA—prostate cancer	6.55e-06	3.28e-05	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—AKT1—prostate cancer	6.49e-06	3.25e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Metabolism—AKT1—prostate cancer	6.4e-06	3.21e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—TP53—prostate cancer	6.34e-06	3.18e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—IL6—prostate cancer	6.25e-06	3.13e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—IL6—prostate cancer	5.8e-06	2.91e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—AKT1—prostate cancer	5.76e-06	2.89e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—AKT1—prostate cancer	5.35e-06	2.68e-05	CbGpPWpGaD
